Long synthetic peptides for the production of vaccines and drugs: A technological platform coming of age

Science Translational Medicine

Volumn 2, Issue 50, 2010, Pages

  Corradin, Giampietro ^a   Kajava, Andrey V ^b   Verdini, Antonio ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGY VACCINE; ANTIALLERGIC AGENT; CANCER VACCINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; IMMUNOLOGICAL ADJUVANT; LONG SYNTHETIC PEPTIDE DERIVATIVE; MALARIA VACCINE; PEPTIDE DERIVATIVE; RANTES; TETRAPEPTIDE; UNCLASSIFIED DRUG; WART VIRUS VACCINE; PEPTIDE; VACCINE;

AMINO TERMINAL SEQUENCE; BIOTECHNOLOGY; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG SYNTHESIS; HUMAN; HUMORAL IMMUNITY; MALARIA FALCIPARUM; NONHUMAN; OVARY CANCER; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; STRUCTURAL BIOINFORMATICS; VACCINE PRODUCTION; VAGINAL INTRAEPITHELIAL NEOPLASIA; BIOLOGY; CHEMISTRY; GENOMICS; IMMUNOLOGY; METHODOLOGY; SYNTHESIS;

COMPUTATIONAL BIOLOGY; GENOMICS; MALARIA VACCINES; PEPTIDES; VACCINES;

EID: 77958048566     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001387     Document Type: Review

References (50)

1. M. Bergmann, L. Zervas, Über ein allgemeines verfahren der peptid-synthese. Ber. Deutsch. Chem. Ges. 65, 1192-1201 (1932).
2. V. du Vigneaud, C. Ressler, J. M. Swan, C. W. Roberts, P. G. Katsoyannis, The synthesis of oxytocin. J. Am. Chem. Soc. 76, 3115-3121 (1954).
3. R. Schwyzer, P. Sieber, Total synthesis of adrenocorticotrophic hormone. Nature 199, 172-174 (1963).
4. R. B. Merrifield, Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149-2154 (1963).
5. E. Atherton, R. C. Sheppard, Solid Phase Peptide Synthesis: A Practical Approach (IRL Press, Oxford, 1989).
6. S. B. H. Kent, Chemical synthesis of peptides and proteins. Annu. Rev. Biochem. 57, 957-989 (1988).
7. S. Olugbile, C. Habel, C. Servis, F. Spertini, A. Verdini, G. Corradin, Malaria vaccines-the long synthetic peptide approach: Technical and conceptual advancements. Curr. Opin. Mol. Ther. 12, 64-76 (2010).
8. M. A. Hossain, A. Belgi, F. Lin, S. Zhang, F. Shabanpoor, L. Chan, C. Belyea, H.-T. Truong, A. R. Blair, S. Andrikoupolos, G. W. Tregear, J. D. Wade, Use of a temporary "solubilizing" peptide tag for the Fmoc solid-phase synthesis of human insulin glargine via use of regioselective disulfide bond formation. Bioconjug. Chem. 20, 1390-1396 (2009).
9. N. Robertson, R. Ramage, Total chemical synthesis of deglycosylated human erythropoietin. J. Chem. Soc. Perkin Trans. 1, 1015-1021 (1999).
10. W. M. Kazmierski, J. McDermed, Synthesis of the carbonic acid benzotriazol-1-yl-ester-(2- biotinylamino)-9H-fluoren-9-ylmethyl ester: A convenient transient-biotinylation reagent for use in affinity chromatography. Tetrahedron Lett. 36, 9097-9100 (1995).
11. M. A. Roggero, C. Servis, G. Corradin, A simple and rapid procedure for the purification of synthetic polypeptides by a combination of affinity chromatography and methionine chemistry. FEBS Lett. 408, 285-288 (1997).
12. J. Vizzavona, M. Villain, K. Rose, Covalent capture purification of polypeptides after SPPS via a linker removable under very mild conditions. Tetrahedron Lett. 8693-8696 (2002).
13. T. Hara, A. Tainosho, K. Nakamura, T. Sato, T. Kawakami, S. Aimoto, Peptide purification by affinity chromatography based on α-ketoacyl group chemistry. J. Pept. Sci. 15, 369-376 (2009).
14. A. Verdini, S. Terenzi, V. Brossard, M. Roggero, G. Corradin, Oxidative folding of synthetic polypeptides S-protected as tert-butylthio derivatives. J. Pept. Sci. 14, 1271-1282 (2008).
15. J. B. Dame, J. L. Williams, T. F. McCutchan, J. L. Weber, R. A. Wirtz, W. T. Hockmeyer, W. L. Maloy, J. D. Haynes, I. Schneider, D. Roberts, G. S. Sanders, E. P. Reddy, C. L. Diggs, L. H. Miller, Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593-599 (1984).
16. E. H. Nardin, R. S. Nussenzweig, T cell responses to pre-erythrocytic stages of malaria: Role in protection and vaccine development against pre-erythrocytic stages. Annu. Rev. Immunol. 11, 687-727 (1993).
17. + T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 31, 1989-1998 (2001).
18. R. Audran, F. Lurati-Ruiz, B. Genton, H. E. Blythman, O. Ofori-Anyinam O, C. Reymond, G. Corradin, F. Spertini, The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: A randomized controlled phase I trial. PLoS One 4, e7304 (2009).
19. B. Genton, V. D'Acremont, F. Lurati-Ruiz, D. Verhage, R. Audran, C. Hermsen, L. Wolters, C. Reymond, F. Spertini, R. Sauerwein, Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine 28, 6573-6580 (2010).
20. S. Herrera, O. L. Fernández, O. Vera, W. Cárdenas, O. Ramírez, R. Palacios, M. Chen-Mok, G. Corradin, M. Arévalo- Herrera, Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with Montanide ISA 720 or Montanide ISA 51. Am. J. Trop. Med. Hyg., in press.
21. S. B. Sirima, A. B. Tiono, A. Ouédraogo, A. Diarra, A. L. Ouédraogo, J. B. Yaro, E. Ouédraogo, A. Gansané, E. C. Bougouma, A. T. Konaté, Y. Kaboré, A. Traoré, R. Chilengi, I. Soulama, A. J. Luty, P. Druilhe, S. Cousens, I. Nébié, Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One 4, e7549 (2009).
22. J. P. Lusingu, S. Gesase, S. Msham, F. Francis, M. Lemnge, M. Seth, S. Sembuche, A. Rutta, D. Minja, M. D. Segeja, S. Bosomprah, S. Cousens, R. Noor, R. Chilengi, P. Druilhe, Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar. J. 8, 163 (2009).
23. M. Esen, P. G. Kremsner, R. Schleucher, M. Gässler, E. B. Imoukhuede, N. Imbault, O. Leroy, S. Jepsen, B. W. Knudsen, M. Schumm, J. Knobloch, M. Theisen, B. Mordmüller, Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 27, 6862-6868 (2009).
24. C. Widmann, P. Romero, J. L. Maryanski, G. Corradin, D. Valmori, T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods 155, 95-99 (1992).
25. G. G. Kenter, M. J.Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van derMeer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, S. H. van der Burg, C. J. Melief, Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
26. N. Leffers, A. J. Lambeck, M. J. Gooden, B. N. Hoogeboom, R. Wolf, I. E. Hamming, B. G. Hepkema, P. H. Willemse, B. H. Molmans, H. Hollema, J. W. Drijfhout, W. J. Sluiter, A. R. Valentijn, L. M. Fathers, J. Oostendorp, A. G. van der Zee, C. J. Melief, S. H. van der Burg, T. Daemen, H. W. Nijman, Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int. J. Cancer 125, 2104-2113 (2009).
27. C. J. Melief, S. H. van der Burg, Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8, 351-360 (2008).
28. C. von Garnier, M. Astori, A. Kettner, N. Dufour, C. Heusser, G. Corradin, F. Spertini, Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur. J. Immunol. 30, 1638-1645 (2000).
29. F. Spertini, personal communication.
30. H. Gaertner, F. Cerini, J. M. Escola, G. Kuenzi, A. Melotti, R. Offord, I. Rossitto-Borlat, R. Nedellec, J. Salkowitz, G. Gorochov, D. Mosier, O. Hartley, Highly potent, fully recombinant anti- HIV chemokines: Reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. U.S.A. 105, 17706-17711 (2008).
31. O. Hartley, personal communication.
32. L. Martin, C. Vita, Engineering novel bioactive mini-proteins from small size natural and de novo designed scaffolds. Curr. Protein Pept. Sci. 1, 403-430 (2000).
33. M. E. Houston Jr., A. Wallace, E. Bianchi, A. Pessi, R. S. Hodges, Use of a conformationally restricted secondary structural element to display peptide libraries: A two-stranded α-helical coiled-coil stabilized by lactam bridges. J. Mol. Biol. 262, 270-282 (1996).
34. C. C. Huang, F. Stricher, L. Martin, J. M. Decker, S. Majeed, P. Barthe, W. A. Hendrickson, J. Robinson, C. Roumestand, J. Sodroski, R. Wyatt, G. M. Shaw, C. Vita, P. D. Kwong, Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 13, 755-768 (2005).
35. C. T. Wild, D. C. Shugars, T. K. Greenwell, C. B. McDanal, T. J. Matthews, Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 91, 9770-9774 (1994).
36. R. Miceli, D. Myszka, J. Mao, G. Sathe, I. Chaiken, The coiled coil stem loop miniprotein as a presentation scaffold. Drug Des. Discov. 13, 95-105 (1996).
37. S. M. Lu, R. S. Hodges, A de novo designed template for generating conformation-specific antibodies that recognize α-helices in proteins. J. Biol. Chem. 277, 23515-23524 (2002).
38. R. Rappuoli, Reverse vaccinology. Curr. Opin. Microbiol. 3, 445-450 (2000).
39. B. Capecchi, D. Serruto, J. Adu-Bobie, R. Rappuoli, M. Pizza, The genome revolution in vaccine research. Curr. Issues Mol. Biol. 6, 17-27 (2004).
40. V. Villard, G. W. Agak, G. Frank, A. Jafarshad, C. Servis, I. Nébié, S. B. Sirima, I. Felger, M. Arevalo-Herrera, S. Herrera, F. Heitz, V. Bäcker, P. Druilhe, A. V. Kajava, G. Corradin, Rapid identification of malaria vaccine candidates based on a-helical coiled coil protein motif. PLoS One 2, e645 (2007).
41. P. B. Harbury, T. Zhang, P. S. Kim, T. Alber, A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262, 1401-1407 (1993).
42. G. W. Agak, P. Bejon, G. Fegan, N. Gicheru, V. Villard, A. V. Kajava, K. Marsh, G. Corradin, Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya. Vaccine 26, 1963-1971 (2008).
43. B. Kobe, A. V. Kajava, When protein folding is simplified to protein coiling: The continuum of solenoid protein structures. Trends Biochem. Sci. 25, 509-515 (2000).
44. A. V. Kajava, A. C. Steven, The turn of the screw: Variations of the abundant b-solenoid motif in passenger domains of type V secretory proteins. J. Struct. Biol. 155, 306-315 (2006).
45. P. E. Wright, J. H. Dyson, Intrinsically unstructured proteins: Re-assessing the protein structure-function paradigm. J. Mol. Biol. 293, 321-331 (1999).
46. S. Olugbile, C. Kulangara, G. Bang, S. Bertholet, E. Suzarte, V. Villard, G. Frank, R. Audran, A. Razaname, I. Nebie, O. Awobusuyi, F. Spertini, A. V. Kajava, I. Felger, P. Druilhe, G. Corradin, Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c. Infect. Immun. 77, 5701-5709 (2009).
47. P. E. Dawson, T. W. Muir, I. Clark-Lewis, S. B. Kent, Synthesis of proteins by native chemical ligation. Science 266, 776-779 (1994).
48. The P. falciparum, L. major, and bacterial genomes were downloaded from http://plasmodb. org, ftp://ftp.sanger.ac.uk/pub/databases/L.major-sequences/ DATASETS/, and ftp://ftp.ncbi. nih.gov/genomes/, correspondingly. The α-helical coiled-coil regions were identified by using generalized sequence profiles as described (40). β-Solenoid fragments were identified by using the CRBM library of profiles (44) (http://bioinfo.montp.cnrs.fr/?p= profiles&r=profiles). Membrane (M) and (or) secreted (S) proteins were selected by using generalized sequence profiles of typical transmembrane regions and the N-terminal signal peptides (49). Unstructured regions were identified by calculating TopIDP index in the 30-residue sliding window (50).
49. P. Bucher, K. Karplus, N. Moeri, K. Hofmann, A flexible motif search technique based on generalized profiles. Comput. Chem. 20, 3-23 (1996).
50. A. Campen, R. M. Williams, C. J. Brown, J. Meng, V. N. Uversky, A. K. Dunker, TOP-IDP-scale: A new amino acid scale measuring propensity for intrinsic disorder. Protein Pept. Lett. 15, 956-963 (2008).